Who are Avilar Therapeutics's investors?

Avilar Therapeutics's investors include Astellas Venture Management LLC, Medical Excellence Capital, RA Capital, Sanofi Ventures, OpenSky Ventures.

How much funding has Avilar Therapeutics raised?

Avilar Therapeutics has disclosed $75.3M raised across 1 round.

Where is Avilar Therapeutics headquartered?

Avilar Therapeutics is headquartered in Waltham, US.

Avilar Therapeutics

Waltham, US · Founded 2020 · Massachusetts corporation · 5 known investors

Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process. The company applies its drug discovery platform to create degraders as potential treatments for serious diseases.

Biotech

Founders & leadership

THERESA CAMERONNamed on SEC filing

MARTIN FREEDNamed on SEC filing

STEPHANIE TOZZONamed on SEC filing

PHIL GRAHAMNamed on SEC filing

MILIND DESHPANDENamed on SEC filing

DAVID NEAFUSNamed on SEC filing

DANIEL GRAUNamed on SEC filing

ADAM MUZIKANTNamed on SEC filing

Board

PAULINA HILL inBoard MemberPartner at Sanofi Ventures

JOSHUA RESNICK in 𝕏Board directorCo-Founder & General Partner at OpenSky Ventures

Investors · 5

Astellas Venture Management LLCSouth San Francisco · $200K – $5M

Medical Excellence CapitalNew York

RA CapitalBoston

Sanofi VenturesCambridge · $5M

OpenSky VenturesreportedLos Angeles

Reported raises · per SEC filings

Form D private placements

$75.3M disclosed across 1 round · 2020

▶$75.3MraisedFeb 2023 · 5 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

THERESA CAMERONDirector
PAULINA HILLDirector
MARTIN FREEDDirector
STEPHANIE TOZZOExecutive Officer
PHIL GRAHAMExecutive Officer
MILIND DESHPANDEDirector
DAVID NEAFUSExecutive Officer
DANIEL GRAUExecutive Officer, Director
ADAM MUZIKANTExecutive Officer
JOSHUA RESNICKDirector

Offering amount: $75.3M
Amount sold: $75.3M
First sale: Dec 2020
Incorporated: Corporation, Massachusetts, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Aclaris Therapeutics8 shared keywordsAclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.

Companies competing with Avilar Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Avilar Therapeutics do?: Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process. The company applies its drug discovery platform to create degraders as potential treatments for serious diseases.
Who are Avilar Therapeutics's investors?: Avilar Therapeutics's investors include Astellas Venture Management LLC, Medical Excellence Capital, RA Capital, Sanofi Ventures, OpenSky Ventures.
How much funding has Avilar Therapeutics raised?: Avilar Therapeutics has disclosed $75.3M raised across 1 round.
Where is Avilar Therapeutics headquartered?: Avilar Therapeutics is headquartered in Waltham, US.